Hypera S.A. (HYPMY) ist ein börsennotiertes Unternehmen im Gesundheitswesen Sektor, tätig in der Drug Manufacturers - Specialty & Generic Branche. Der Hauptsitz des Unternehmens ist in São Paulo, SP, Brazil. Der aktuelle CEO ist Breno Toledo Pires de Oliveira.
HYPMY hat IPO-Datum 2010-10-15, 10,481 Vollzeitbeschäftigte, gelistet an der Other OTC, eine Marktkapitalisierung von $3.29B.
Hypera S.A. is a leading Brazilian pharmaceutical company offering a comprehensive portfolio of prescription medications, generic drugs, dermo-cosmetics, consumer health products, and nutritional supplements. The company markets well-established brands across multiple therapeutic categories, including dermatology, pain management, gastrointestinal, and respiratory products, alongside popular over-the-counter remedies and vitamin lines. Operating from its headquarters in São Paulo, Hypera serves the Brazilian market through diverse distribution channels, combining branded pharmaceuticals with cost-effective generic alternatives to address various healthcare needs. The company, formerly known as Hypermarcas S.A., rebranded to Hypera S.A. in February 2018 to reflect its pharmaceutical-focused strategy.
